Micafungin for empirical antifungal therapy in patients with febrile neutropenia: multicenter phase 2 study

[1]  M. Ruhnke,et al.  Antifungal treatment strategies in patients with haematological diseases or cancer: from prophylaxis to empirical, pre‐emptive and targeted therapy , 2012, Mycoses.

[2]  T. Naoe,et al.  Efficacy and safety of micafungin as an empirical antifungal therapy for suspected fungal infection in neutropenic patients with hematological disorders , 2012, Annals of Hematology.

[3]  K. Ishiyama,et al.  Efficacy and safety of micafungin as an empirical therapy for invasive fungal infections in patients with hematologic disorders: a multicenter, prospective study , 2011, Annals of Hematology.

[4]  A. Thiébaut,et al.  European guidelines for antifungal management in leukemia and hematopoietic stem cell transplant recipients: summary of the ECIL 3—2009 Update , 2011, Bone Marrow Transplantation.

[5]  K. Sepkowitz,et al.  IDSA GUIDELINES Clinical Practice Guideline for the Use of Antimicrobial Agents in Neutropenic Patients with Cancer: 2010 Update by the Infectious Diseases Society of America , 2022 .

[6]  M. Shimizu,et al.  Efficacy and safety of micafungin for treating febrile neutropenia in hematological malignancies , 2010, American journal of hematology.

[7]  Jin-Hyuk Choi,et al.  Efficacy and Safety of Micafungin as An Empirical Antifungal Agent for Febrile Neutropenic Patients with Hematological Diseases. , 2009 .

[8]  A. Vekhoff,et al.  Empirical versus preemptive antifungal therapy for high-risk, febrile, neutropenic patients: a randomized, controlled trial. , 2009, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

[9]  T. Rogers,et al.  Newer antifungal agents for invasive fungal infections in patients with haematological malignancy , 2009, British journal of haematology.

[10]  Y. Kakinoki,et al.  Efficacy and safety of micafungin in febrile neutropenic patients treated for hematological malignancies. , 2007, Internal medicine.

[11]  C. Viscoli,et al.  Empirical antifungal therapy in patients with neutropenia and persistent or recurrent fever of unknown origin , 2006, British journal of haematology.

[12]  T. Naoe,et al.  Micafungin, a novel antifungal agent, as empirical therapy in acute leukemia patients with febrile neutropenia. , 2006, Internal medicine.

[13]  D. Kontoyiannis,et al.  Invasive fungal infections in patients with hematologic malignancies in a tertiary care cancer center: an autopsy study over a 15-year period (1989-2003). , 2006, Haematologica.

[14]  Thomas J Walsh,et al.  Caspofungin versus liposomal amphotericin B for empirical antifungal therapy in patients with persistent fever and neutropenia. , 2004, The New England journal of medicine.

[15]  D. Denning.  Echinocandin antifungal drugs , 2003, The Lancet.

[16]  D. Denning,et al.  Activity of micafungin (FK463) against an itraconazole-resistant strain of Aspergillus fumigatus and a strain of Aspergillus terreus demonstrating in vivo resistance to amphotericin B. , 2003, Journal of Antimicrobial Chemotherapy.

[17]  T. Calandra,et al.  Guidelines for the Use of Antimicrobial Agents in Neutropenic Patients with Cancer , 2002 .

[18]  E. Anaissie,et al.  Voriconazole compared with liposomal amphotericin B for empirical antifungal therapy in patients with neutropenia and persistent fever. , 2002, The New England journal of medicine.

[19]  D. Denning,et al.  Defining opportunistic invasive fungal infections in immunocompromised patients with cancer and hematopoietic stem cell transplants: an international consensus. , 2002, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

[20]  A. Schwarer,et al.  Intravenous and Oral Itraconazole versus Intravenous Amphotericin B Deoxycholate as Empirical Antifungal Therapy for Persistent Fever in Neutropenic Patients with Cancer Who Are Receiving Broad-Spectrum Antibacterial Therapy , 2001, Annals of Internal Medicine.

[21]  Koji Kawabata,et al.  In Vitro Activities of a New Lipopeptide Antifungal Agent, FK463, against a Variety of Clinically Important Fungi , 2000, Antimicrobial Agents and Chemotherapy.

[22]  R. Finberg,et al.  Liposomal Amphotericin B for Empirical Therapy in Patients with Persistent Fever and Neutropenia , 1999 .

[23]  R. Finberg,et al.  Liposomal amphotericin B for empirical therapy in patients with persistent fever and neutropenia. National Institute of Allergy and Infectious Diseases Mycoses Study Group. , 1999, The New England journal of medicine.

[24]  S. Khan,et al.  A randomized comparison of fluconazole with amphotericin B as empiric anti-fungal agents in cancer patients with prolonged fever and neutropenia. , 1998, The American journal of medicine.

[25]  F. Meunier.  Empirical antifungal therapy in febrile granulocytopenic patients , 1989 .

[26]  Empiric antifungal therapy in febrile granulocytopenic patients. EORTC International Antimicrobial Therapy Cooperative Group. , 1989, The American journal of medicine.

[27]  F. Witebsky,et al.  Empiric antibiotic and antifungal therapy for cancer patients with prolonged fever and granulocytopenia. , 1982, The American journal of medicine.